Search Result

Isoforms Recommended:	PLK3

Results for "

PLK3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (2) Apoptosis (4) Autophagy (4) Btk (2) JAK (2) Organoid (2) PI3K (2) Polo-like Kinase (PLK) (16) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (15) Cardiovascular Disease (1) Inflammation/Immunology (1)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Recombinant Proteins

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15161

Ro3280 4 Publications Verification	Polo-like Kinase (PLK)	Cancer
Ro3280 is a potent, highly selective inhibitor of *PLK1* with an IC₅₀ and a K_d of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.

HY-108597

TC-S 7005 2 Publications Verification	Polo-like Kinase (PLK)	Cardiovascular Disease Inflammation/Immunology
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively .

HY-15158

SBE13 Hydrochloride	Polo-like Kinase (PLK) Autophagy Apoptosis	Cancer
SBE13 Hydrochloride is a potent and selective *Plk1* inhibitor, with an IC₅₀ of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-11003

GW843682X 5 Publications Verification GW843682	Polo-like Kinase (PLK)	Cancer
GW843682X is a selective, ATP-competitive inhibitor of *PLK1* and *PLK3, with IC₅₀*s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ～30 other kinases.

HY-18009

(Z)-LFM-A13 3 Publications Verification	Btk Polo-like Kinase (PLK) JAK	Cancer
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

HY-10197

Wortmannin Maximum Cited Publications 116 Publications Verification SL-2052; KY-12420	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible *PI3K* inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and *Plk3* with IC₅₀s of 5.8 and 48 nM, respectively ^[3].

HY-RS10717

PLK3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PLK3 Human Pre-designed siRNA Set A PLK3 Human Pre-designed siRNA Set A

HY-RS10718

Plk3 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Plk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk3 Mouse Pre-designed siRNA Set A Plk3 Mouse Pre-designed siRNA Set A

HY-RS10719

Plk3 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Plk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk3 Rat Pre-designed siRNA Set A Plk3 Rat Pre-designed siRNA Set A

HY-15158A

SBE13	Polo-like Kinase (PLK) Autophagy	Cancer
SBE13 is a potent and selective *Plk1* inhibitor, with an IC₅₀ of 200 pM; SBE13 poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-110002

LFM-A13 1 Publications Verification	Polo-like Kinase (PLK) Btk JAK	Cancer
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research ^[3]

HY-12137

Volasertib 20+ Cited Publications BI 6727	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-12137A

Volasertib trihydrochloride BI 6727 trihydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-15160

TAK-960 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160B

TAK-960 dihydrochloride 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-15160A

TAK-960 hydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-115589

YLT-11	Polo-like Kinase (PLK) Apoptosis	Cancer
YLT-11 is a potent, selective and orally active *PLK4* inhibitor with K_d values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity .

HY-10197R

Wortmannin (Standard)	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively ^[3].

HY-15160C

TAK-960 monohydrochloride	Polo-like Kinase (PLK)	Cancer
TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

Cat. No.	Product Name	Type

HY-110002

LFM-A13 1 Publications Verification	Biochemical Assay Reagents
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research ^[3]

Wortmannin 115+ Cited Publications SL-2052; KY-12420	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible *PI3K* inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and *Plk3* with IC₅₀s of 5.8 and 48 nM, respectively ^[3].

Wortmannin (Standard)	Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively ^[3].

Cat. No.	Compare	Product Name	Species	Source

HY-P702889

	PLK3 Polo Box Domain Protein, Human (MBP, His) CNK; FNK; PRK	Human	E. coli
	PLK3 Polo Box Domain Protein, Human (MBP, His) is the recombinant human-derived PLK3 Polo Box Domain, expressed by E. coli , with C-6*His, N-MBP labeled tag. ,

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

PLK3 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
PLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk3 Mouse Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Plk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Plk3 Rat Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
Plk3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks